InspireMD (STU:II2) YoY EPS Growth: 34.22% (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

STU:II2 InspireMD Inc STU:II2
47 GF Score
Price €0.77
GF Value €1.39
Valuation Possible Value Trap
! 3 Warning Signs
View Full Analysis

What is InspireMD YoY EPS Growth?

InspireMD STU:II2 +4.05% 47 YoY EPS Growth is 34.22% as of Jun. 2026. GuruFocus rates STU:II2 with a GF Score™ of 47/100 and a GF Value™ of €1.39 (Possible Value Trap). The stock has 3 warning signs investors should review.

YoY EPS Growth is the percentage change of Earnings per Share (Diluted) over the past twelve months. InspireMD's YoY EPS Growth for the quarter that ended in Jun. 2026 was 34.22%.

InspireMD's Earnings per Share (Diluted) for the three months ended in Jun. 2026 was €-0.15.

InspireMD YoY EPS Growth Historical Data

* Premium members only.

The historical data trend for InspireMD's YoY EPS Growth can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

InspireMD YoY EPS Growth Chart

InspireMD Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
YoY EPS Growth
Get a 7-Day Free Trial Premium Member Only Premium Member Only 68.63 -23.43 66.10 3.46 10.61

InspireMD Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
YoY EPS Growth Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -10.29 -0.69 33.70 32.02 34.22
STU:II2
47GF Score
InspireMD Inc STU:II2
YoY EPS Growth is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

InspireMD YoY EPS Growth Calculation

YoY EPS Growth is the percentage change of Earnings per Share (Diluted) over the past twelve months.

InspireMD's YoY EPS Growth for the fiscal year that ended in Dec. 2025 is calculated as:

YoY EPS Growth (A: Dec. 2025 )
=(Earnings per Share (Diluted) (A: Dec. 2025 )-Earnings per Share (Diluted) (A: Dec. 2024 ))/ | Earnings per Share (Diluted) (A: Dec. 2024 ) |
=(-0.649--0.726)/ | -0.726 |
=10.61 %

InspireMD's YoY EPS Growth for the quarter that ended in Jun. 2026 is calculated as:

YoY EPS Growth (Q: Jun. 2026 )
=(Earnings per Share (Diluted) (Q: Jun. 2026 )-Earnings per Share (Diluted) (Q: Jun. 2025 )) / | Earnings per Share (Diluted) (Q: Jun. 2025 )) |
=(-0.148--0.225)/ | -0.225 |
=34.22 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about YoY EPS Growth →
What does a YoY EPS Growth of 34.22% mean?
InspireMD (STU:II2) has a YoY EPS Growth of 34.22% as of Jun. 2026. YoY EPS Growth is the percentage change of EPS over the past 12-month. View historical data for InspireMD and its competitors.
Is InspireMD's YoY EPS Growth too high?
InspireMD's current YoY EPS Growth is 34.22%. Overall, InspireMD has a GF Score™ of 47/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does InspireMD's YoY EPS Growth compare to SNWV and PAVM?
InspireMD's YoY EPS Growth of 34.22% can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good YoY EPS Growth for a Medical Devices & Instruments company?
A good YoY EPS Growth depends on the Medical Devices & Instruments industry context. However, YoY EPS Growth should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high YoY EPS Growth mean?
A high YoY EPS Growth can signal that a stock is expensive relative to its fundamentals. YoY EPS Growth is the percentage change of EPS over the past 12-month. View historical data for InspireMD and its competitors. InspireMD's current YoY EPS Growth is 34.22%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is InspireMD stock overvalued right now?
Based on GuruFocus' analysis, InspireMD (STU:II2) is currently considered Possible Value Trap. The stock's GF Value™ is €1.39, compared to a current price of €0.77 — trading 44.6% below its estimated fair value. The current YoY EPS Growth is 34.22%. InspireMD's overall GF Score™ is 47/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is YoY EPS Growth calculated?
YoY EPS Growth is calculated from a company's financial statements. For InspireMD (STU:II2), the current YoY EPS Growth is 34.22% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is InspireMD (STU:II2) Overvalued in 2026?

Based on GuruFocus' analysis, InspireMD stock appears to be undervalued. The current stock price of €0.77 is trading 44.6% below its estimated GF Value™ of €1.39. GuruFocus considers InspireMD to be Possible Value Trap.

Key valuation signals for STU:II2:

  • YoY EPS Growth: 34.22%
  • GF Value™: €1.39 vs. price of €0.77 (44.6% below fair value)
  • GF Score™: 47/100 with 3 warning signs

No single metric tells the full story. See the STU:II2 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

InspireMD Business Description

Other Exchanges NSPR:USA
Address 6303 Waterford District Drive, Suite 215, Miami, FL, USA, 33126
InspireMD Inc is a United States-based medical device company. It is focused on the development and commercialization of proprietary MicroNet stent platform technology for the treatment of complex vascular and coronary disease. The products of the company are the CGuard carotid Embolic Prevention System (CGuard EPS) and the MGuard Prime Embolic Protection System. It generates the majority of the revenue from the sales of CGuard EPS, which combines MicroNet and a self-expandable nitinol stent in a single device for use in carotid artery applications. The Company has one operating and reporting segment that develops, manufactures, and markets products for the treatment of carotid artery disease and other vascular diseases, including the Company's proprietary CGuard stent platform.
47GF Score

Get the complete analysis for STU:II2

YoY EPS Growth is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€0.77
Price
€1.39
GF Value